Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 2h
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023Business Wire • Wednesday
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx ConferenceBusiness Wire • 11/22/23
Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy OpportunitySeeking Alpha • 11/13/23
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple SclerosisBusiness Wire • 11/08/23
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial ResultsBusiness Wire • 11/01/23
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 10/06/23
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on ComparabilityBusiness Wire • 09/19/23
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 09/01/23
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma ConferenceBusiness Wire • 08/31/23
Atara Biotherapeutics: A Speculative Buy On Upcoming Phase 2 Multiple Sclerosis ReadoutSeeking Alpha • 08/21/23
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/23
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational ProgressBusiness Wire • 08/08/23
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023Business Wire • 08/01/23
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceBusiness Wire • 07/31/23
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare ConferenceBusiness Wire • 06/07/23